Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Total Non-Current Liabilities (2016 - 2025)

Enanta Pharmaceuticals (ENTA) has disclosed Total Non-Current Liabilities for 14 consecutive years, with $215.8 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Total Non-Current Liabilities fell 12.86% year-over-year to $215.8 million, compared with a TTM value of $215.8 million through Sep 2025, down 12.86%, and an annual FY2025 reading of $215.8 million, down 12.86% over the prior year.
  • Total Non-Current Liabilities was $215.8 million for Q3 2025 at Enanta Pharmaceuticals, down from $229.2 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $247.6 million in Q3 2024 and bottomed at $31.7 million in Q2 2021.
  • Average Total Non-Current Liabilities over 5 years is $133.7 million, with a median of $56.7 million recorded in 2023.
  • The sharpest move saw Total Non-Current Liabilities soared 363.63% in 2023, then dropped 12.86% in 2025.
  • Year by year, Total Non-Current Liabilities stood at $55.7 million in 2021, then dropped by 5.45% to $52.7 million in 2022, then soared by 348.15% to $236.0 million in 2023, then grew by 0.26% to $236.6 million in 2024, then dropped by 8.81% to $215.8 million in 2025.
  • Business Quant data shows Total Non-Current Liabilities for ENTA at $215.8 million in Q3 2025, $229.2 million in Q1 2025, and $236.6 million in Q4 2024.